• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Kestra Medical Technologies Ltd.

    5/15/25 5:15:21 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care
    Get the next $KMTS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Kestra Medical Technologies, Ltd.

    (Name of Issuer)


    Common Shares, par value $1.00 per share

    (Title of Class of Securities)


    G52441105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G52441105


    1Names of Reporting Persons

    Bain Charger Holdings, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    24,949,838.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    27,019,225.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    27,019,225.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    52.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Kestra Medical Technologies, Ltd.
    (b)Address of issuer's principal executive offices:

    3933 Lake Washington BLVD NE, Suite 200, Kirkland, WA 98003
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed by Bain Charger Holdings, L.P., a Delaware limited partnership (the "Reporting Person"). Bain Capital Investors, LLC, a Delaware limited liability company ("BCI" and, together with the Reporting Person, the "Bain Capital Entities"), is the general partner of the Reporting Person. As a result, BCI may be deemed to share voting and dispositive power with respect to the securities held by Bain Charger. Voting and investment decisions with respect to the securities held by the Reporting Person are made by the partners of BCI.
    (b)Address or principal business office or, if none, residence:

    The principal business address for each of the Bain Capital Entities is 200 Clarendon Street, Boston, MA 02116.
    (c)Citizenship:

    Each of the Bain Capital Entities is organized under the laws of the State of Delaware.
    (d)Title of class of securities:

    Common Shares, par value $1.00 per share
    (e)CUSIP No.:

    G52441105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of the close of business on March 31, 2025, the Reporting Person directly held 7,109,944 Common Shares, representing approximately 13.8% of the Issuer's outstanding Common Shares, and West Affum Holdings, L.P. ("West Affum") directly held 19,909,281 Common Shares, representing approximately 38.8% of the Issuer's outstanding Common Shares. The Common Shares held directly by West Affum are held for the benefit of the holders of West Affum common units, including the Reporting Person, until the time such Common Shares are distributed to the holders of West Affum common units in accordance with the partnership agreement of West Affum. The Reporting Person is the sole shareholder of West Affum GP Ltd., which is the general partner of West Affum. As a result of the foregoing, and the relationships described in Item 2(a) of this Schedule 13G, the Reporting Person may be deemed to have (ii) shared voting power with respect to an aggregate of 24,949,838 Common Shares, representing (x) 7,109,944 Common Shares held directly by the Reporting Person and (y) 17,839,894 Common Shares indirectly held by the Reporting Person through West Affum, and (ii) shared dispositive power with respect to an aggregate of 27,019,225 Common Shares. The percentage of the outstanding Common Shares held by the Reporting Person is based on 51,348,656 Common Shares outstanding as of April 17, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 17, 2025.
    (b)Percent of class:

    See Item 4(a) hereof.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See Item 4(a) hereof.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 4(a) hereof.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Bain Charger Holdings, L.P.
     
    Signature:/s/ Chris Gordon
    Name/Title:Chris Gordon, Partner of Bain Capital Investors, LLC
    Date:05/15/2025
    Get the next $KMTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMTS

    DatePrice TargetRatingAnalyst
    3/31/2025$30.00Buy
    BofA Securities
    3/31/2025$29.00Outperform
    Wolfe Research
    3/31/2025$24.00Neutral
    Goldman
    3/31/2025$28.00Buy
    Stifel
    3/31/2025$28.00Overweight
    Wells Fargo
    3/31/2025$27.00Overweight
    Piper Sandler
    More analyst ratings

    $KMTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Raymond W was granted 12,994 shares (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    7/24/25 4:10:50 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Officer Webster Brian Daniel was granted 88,235 shares, increasing direct ownership by 29% to 397,577 units (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    7/21/25 5:20:31 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Mahboob Vaseem was granted 22,059 shares, increasing direct ownership by 149% to 36,897 units (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    7/21/25 5:14:36 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biobeat Technologies Names Raymond W. Cohen as Chairman of the Board of Directors

    Biobeat Technologies Ltd, a medical device company that has developed a wearable cuff-less ambulatory blood pressure monitoring system that records and analyzes numerous physiological parameters, today announced the appointment of Raymond W. Cohen as its Chairman of the Board of Directors. Biobeat developed and has received FDA clearance for an easy-to-apply "patch" device that can collect, record and transmit patient data to a cloud-based data center for AI-aided analysis and reporting of physiological parameters, including continuous cuff-less ambulatory blood pressure (ABPM), Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output. "We welcome

    8/21/25 7:00:00 AM ET
    $KMTS
    $NSPR
    $RXST
    Medical/Dental Instruments
    Health Care
    Ophthalmic Goods

    RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

    ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. "We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors," said J. Andy Corley, Chairman of the Board at RxSight. "Ray's extensive track record in leading and scaling medical technology companies will be invaluable as we advance our strategy and enter the next phase of growth. His insights and guidance will help us expand the reach of the RxSight® Light Adjustable Lens system,

    8/4/25 8:05:00 AM ET
    $AXNX
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care
    Ophthalmic Goods

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $KMTS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Kestra Medical Technologies Ltd.

    DEFA14A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    7/22/25 4:09:38 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Kestra Medical Technologies Ltd.

    DEF 14A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    7/22/25 4:06:42 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Kestra Medical Technologies Ltd.

    10-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    7/17/25 4:06:25 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Kestra Medical Technologies with a new price target

    BofA Securities initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $30.00

    3/31/25 8:54:18 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Kestra Medical Technologies with a new price target

    Wolfe Research initiated coverage of Kestra Medical Technologies with a rating of Outperform and set a new price target of $29.00

    3/31/25 8:13:51 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Kestra Medical Technologies with a new price target

    Goldman initiated coverage of Kestra Medical Technologies with a rating of Neutral and set a new price target of $24.00

    3/31/25 8:13:51 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    Financials

    Live finance-specific insights

    View All

    Kestra Medical Technologies Wins 2025 Top Workplaces Industry Award, A National Recognition

    KIRKLAND, Wash., July 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, announced today that it is a 2025 Top Workplaces Industry winner by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 17-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. Top Workplaces Industry awards celebrate organizations that have built people-first workplace cultures within their sector. The award marks them as an employer of choice for those seeking employment in the industry. "Being

    7/17/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies, Ltd. to Report Fourth Quarter and Fiscal Year 2025 Results on July 15

    KIRKLAND, Wash., July 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report fourth quarter and fiscal year 2025 financial results on Tuesday, July 15. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digit

    7/1/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies, Ltd. to Report Third Quarter Fiscal 2025 Financial Results on April 14

    KIRKLAND, Wash., April 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report financial results for the third quarter fiscal 2025 on Monday, April 14. Management will host a corresponding conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable

    4/2/25 4:05:00 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

    BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

    6/23/25 9:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Announces Appointment of Conor Hanley to its Board of Directors

    KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an independent director to its board, effective June 4, 2025. "I am delighted to welcome Conor to our board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "He brings deep expertise in medical technology and cardiac care and will serve as an invaluable strategic resource as we grow and expand the reach of the ASSURE® system." Mr. Hanley is a chartered director and currently serves as CEO of FIRE1, a venture-backed connected medical device sol

    6/5/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care